The company reported worldwide net revenues of $56.3 billion, operating earnings of $9.1 billion, diluted earnings per share of $2.39 and cash flows from operations of $18.8 billion for 2024, and said worldwide net revenues increased 4% on a reported basis and 5% on a constant currency basis.

1. 01

   The company reported worldwide net revenues of $56.3 billion, operating earnings of $9.1 billion, diluted earnings per share of $2.39 and cash flows from operations of $18.8 billion for 2024, and said worldwide net revenues increased 4% on a reported basis and 5% on a constant currency basis.

2. 02

   The company said global Humira sales decreased 37% in 2024 on a constant currency basis, while Skyrizi increased 51% and Rinvoq increased 53%, and cited direct biosimilar competition as the primary driver of the 41% decrease in Humira sales in the United States.

3. 03

   The company said investing activities in 2024 included cash consideration paid to acquire ImmunoGen and Cerevel Therapeutics of $18.5 billion before cash acquired of $952 million, and that it issued unsecured senior notes of $15.0 billion to finance the acquisitions.

4. 04

   The company said it paid cash dividends of $11.0 billion in 2024, repurchased 7 million shares for $1.3 billion and had remaining stock repurchase authorization of $3.5 billion as of December 31, 2024.

Key figures

Fiscal year ended December 31, 2024

Operating income

$9.1B

Net income

$4.3B

EPS

$2.39

Gross profit

$10.7B

Operating cash flow

$18.8B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.